1 week Ago By Defense World Staff
Norges Bank bought a new stake in Intellia Therapeutics, Inc. ( NASDAQ:NTLA – Free Report ) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 30,010 shares of the company’s stock, valued at approximately $350,000.
Several other hedge funds also recently made changes to their positions in the company. Whipplewood Advisors LLC purchased a new position in Intellia Therapeutics during the fourth quarter valued at $40,000. Jones Financial Companies Lllp increased its stake in shares of Intellia Therapeutics by 140.
9% in the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after acquiring an additional 2,280 shares in the last quarter. Daiwa Securities Group Inc.
lifted its position in Intellia Therapeutics by 80.6% during the 4th quarter. Daiwa Securities Group Inc.
now owns 5,151 shares of the company’s stock valued at $60,000 after acquiring an additional 2,299 shares during the period. KBC Group NV boosted its stake in Intellia Therapeutics by 62.4% during the fourth quarter.
KBC Group NV now owns 6,093 shares of the company’s stock worth $71,000 after acquiring an additional 2,340 shares in the last quarter. Finally, AdvisorNet Financial Inc grew its holdings in Intellia Therapeutics by 96.4% in the fourth quarter.
AdvisorNet Financial Inc now owns 10,085 shares of the company’s stock worth $118,000 after purchasing an additional 4,950 shares during the period. 88.77% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In NTLA has been the subject of several recent research reports. Wells Fargo & Company lowered their target price on shares of Intellia Therapeutics from $60.00 to $50.
00 and set an “overweight” rating for the company in a report on Friday, February 28th. Citigroup boosted their target price on Intellia Therapeutics from $12.00 to $14.
00 and gave the stock a “neutral” rating in a report on Friday, February 28th. BMO Capital Markets reduced their price target on Intellia Therapeutics from $70.00 to $50.
00 and set an “outperform” rating for the company in a report on Friday, January 10th. Chardan Capital cut their price objective on shares of Intellia Therapeutics from $91.00 to $68.
00 and set a “buy” rating on the stock in a research report on Friday, February 28th. Finally, HC Wainwright initiated coverage on shares of Intellia Therapeutics in a research note on Wednesday, March 5th. They set a “buy” rating and a $30.
00 price objective for the company. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.
56. Intellia Therapeutics Price Performance Shares of NTLA opened at $7.41 on Friday.
The firm has a market capitalization of $767.06 million, a P/E ratio of -1.36 and a beta of 2.
23. Intellia Therapeutics, Inc. has a one year low of $5.
90 and a one year high of $28.18. The business has a fifty day moving average of $9.
15 and a 200 day moving average of $12.59. Intellia Therapeutics Company Profile ( Free Report ) Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics.
The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. Featured Articles Five stocks we like better than Intellia Therapeutics Want to Profit on the Downtrend? Downtrends, Explained. Robinhood Strategies Could Be a Game-Changer for Young Investors Do ETFs Pay Dividends? What You Need to Know Are These 3 Retail Stocks Oversold or Really in Trouble? 2 Rising CRM Platform Stocks That Can Surge Higher in 2025 IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. ( NASDAQ:NTLA – Free Report ). Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
